{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "DJ1",
        "Protein_Change": {
          "ref": "E",
          "alt": "D",
          "position": "64"
        },
        "variant_string_id": "DJ1 E64D"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the DJ1 gene are associated with autosomal recessive early-onset Parkinson disease (EOPD, PARK7). The paper suggests that DJ1 mutations lead to loss of function, potentially through altered protein stability or localization, contributing to dopaminergic neuron loss.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as autosomal recessive EOPD linked to DJ1 mutations, with a focus on loss of function as a potential pathogenic mechanism through protein instability or mislocalization."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses multiple assays including crystallography to assess protein structure, Western blot to evaluate protein stability, and immunocytochemistry to determine cellular localization of the DJ1 protein in HEK293 and COS7 cells. Additionally, PET scans assess dopamine transporter (DAT) binding as a marker of presynaptic dopaminergic function.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays (crystallography, Western blot, immunocytochemistry, and PET imaging) are relevant to Parkinson disease pathogenesis. They model aspects of protein function, stability, localization, and dopaminergic system integrity, which are implicated in EOPD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blot and immunocytochemistry experiments included wild-type DJ1 as a normal control and L166P mutant as an abnormal control. Experiments were reproduced at least three times as stated in the results section (e.g., 'All experiments were reproduced at least three times with similar results').",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type DJ1) and abnormal (L166P mutant) controls were used in the functional assays. The paper explicitly states that experiments were repeated at least three times, indicating the use of replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The L166P mutation, a known pathogenic variant associated with EOPD, was used as a control in Western blot and immunocytochemistry experiments alongside the E64D variant and wild-type DJ1.",
          "judgment": "Yes",
          "reasoning": "A known pathogenic variant (L166P) was used as a control in the functional assays, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper does not provide specific statistical analyses or OddsPath calculations for the functional data related to E64D. Results are descriptive, focusing on protein levels (Western blot), localization (immunocytochemistry), and DAT binding (PET) without p-values or effect sizes.",
          "judgment": "No",
          "reasoning": "There are no statistical analyses or OddsPath calculations provided in the paper to quantitatively assess the functional impact of the E64D variant.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation - Count of Benign/Pathogenic Variant Controls",
          "extracted_paper_info": "Only one known pathogenic variant control (L166P) was used in the functional assays alongside the wild-type control.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign and pathogenic variant controls used in the study is less than or equal to 10 (specifically, one pathogenic control, L166P, and wild-type as a benign/normal control).",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for DJ1 E64D is rated as PS3_supporting due to the use of relevant assays (crystallography, Western blot, immunocytochemistry, PET) that model aspects of Parkinson disease pathogenesis, inclusion of basic controls and replicates, and use of a known pathogenic variant control (L166P). However, the lack of statistical analyses or OddsPath calculation, combined with a low number of variant controls (â‰¤10), limits the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "DJ1",
        "Protein_Change": {
          "ref": "L",
          "alt": "P",
          "position": "166"
        },
        "variant_string_id": "DJ1 L166P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the DJ1 gene are associated with autosomal recessive early-onset Parkinson disease (EOPD, PARK7). The paper suggests that DJ1 mutations, including L166P, lead to loss of function, potentially through altered protein stability or localization, contributing to dopaminergic neuron loss.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as autosomal recessive EOPD linked to DJ1 mutations, with a focus on loss of function as a potential pathogenic mechanism through protein instability or mislocalization."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses Western blot to evaluate protein stability and immunocytochemistry to determine cellular localization of the DJ1 protein in HEK293 and COS7 cells for the L166P variant.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays (Western blot and immunocytochemistry) are relevant to Parkinson disease pathogenesis. They model aspects of protein function, stability, and localization, which are implicated in EOPD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blot and immunocytochemistry experiments included wild-type DJ1 as a normal control and E64D mutant alongside L166P. Experiments were reproduced at least three times as stated in the results section (e.g., 'All experiments were reproduced at least three times with similar results').",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type DJ1) and abnormal (E64D mutant) controls were used in the functional assays alongside L166P. The paper explicitly states that experiments were repeated at least three times, indicating the use of replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The E64D mutation, under investigation in this paper, was used alongside L166P, but L166P itself is a known pathogenic variant. However, no additional independent known pathogenic or benign variants were used as controls specifically for L166P assessment beyond the wild-type and E64D.",
          "judgment": "No",
          "reasoning": "While L166P is a known pathogenic variant, the assays do not include additional independent known pathogenic or benign variant controls beyond the wild-type and the variant under study (E64D). The criterion requires controls beyond the variant being assessed and wild-type.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for DJ1 L166P is rated as PS3_supporting due to the use of relevant assays (Western blot and immunocytochemistry) that model aspects of Parkinson disease pathogenesis, inclusion of basic controls and replicates. However, the lack of additional independent variant controls beyond wild-type and E64D limits the strength to supporting."
    }
  ]
}